Grifols S.A

Research Grifols S.A (OZTA) on Bullrun: market cap EUR 6.66B, P/E 14.8, dividend yield 0.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 6.66B; P/E is 14.8; dividend yield is 0.8%.

Peer valuation comparison

Latest P/E is 14.83x versus a Healthcare sector median of 24.46x (39.4% below).

Latest dividend yield is 0.82% versus a Healthcare sector median of 2.11% (61.1% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2024EUR 7.21BEUR 212.81MEUR 669.63M38.7%0.23EUR 979.78MEUR 10.11BEUR 5.88B
FY2023EUR 6.59BEUR 163.67M-EUR 5.75M37.7%0.06EUR 529.58Mn/aEUR 5.37B
FY2022EUR 6.06BEUR 247.90M-EUR 285.23M36.5%0.27EUR 549.21Mn/aEUR 5.65B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-15EUR 6.66B14.80.8%0.08

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.08 EUR, yield 0.8%.

About Grifols S.A

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Grifols S.A's market cap?

Grifols S.A's market capitalization is EUR 6.66B.

What is Grifols S.A's P/E ratio?

Grifols S.A's price-to-earnings (P/E) ratio is 14.8.

Does Grifols S.A pay a dividend?

Grifols S.A has a dividend yield of 0.8%.

What does Grifols S.A do?

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.